Spatially resolved transcriptomics of high-grade serous ovarian carcinoma.
Stur E, Corvigno S, Xu M, Chen K, Tan Y, Lee S, Liu J, Ricco E, Kraushaar D, Castro P, Zhang J, Sood AK.
iScience. 2022 Feb 14;25(3):103923. doi: 10.1016/j.isci.2022.103923. eCollection 2022 Mar 18.
The continuum of high ovarian response: a rational approach to the management of high responder patient subgroups.
Gat I, Shlush E, Quach K, Librach CL.
Syst Biol Reprod Med. 2015;61(6):336-44. doi: 10.3109/19396368.2015.1089607. Epub 2015 Oct 30.
The normal menstrual cycle in women.
Mihm M, Gangooly S, Muttukrishna S.
Anim Reprod Sci. 2011 Apr;124(3-4):229-36. doi: 10.1016/j.anireprosci.2010.08.030. Epub 2010 Sep 3.
Patient-Derived Ovarian Cancer Organoids Mimic Clinical Response and Exhibit Heterogeneous Inter- and Intrapatient Drug Responses.
de Witte CJ, Espejo Valle-Inclan J, Hami N, Lõhmussaar K, Kopper O, Vreuls CPH, Jonges GN, van Diest P, Nguyen L, Clevers H, Kloosterman WP, Cuppen E, Snippert HJG, Zweemer RP, Witteveen PO, Stelloo E.
Cell Rep. 2020 Jun 16;31(11):107762. doi: 10.1016/j.celrep.2020.107762.
Patient-derived ovarian cancer organoid carries immune microenvironment and blood vessel keeping high response to cisplatin.
Zhao Y, Wang C, Deng W, Li L, Liu J, Shi Y, Tao X, Zhang J, Cao Q, Cai C, Han X.
MedComm (2020). 2024 Aug 28;5(9):e697. doi: 10.1002/mco2.697. eCollection 2024 Sep.
The Essential Role of Body Weight in Adjusting Gn Dosage to Prevent High Ovarian Response for Women With PCOS During IVF: A Retrospective Study.
Zeng R, Chen H, Zeng X, Qin L.
Front Endocrinol (Lausanne). 2022 Jul 1;13:922044. doi: 10.3389/fendo.2022.922044. eCollection 2022.
Targeting PARG induces tumor cell growth inhibition and antitumor immune response by reducing phosphorylated STAT3 in ovarian cancer.
Martincuks A, Zhang C, Austria T, Li YJ, Huang R, Lugo Santiago N, Kohut A, Zhao Q, Borrero RM, Shen B, Cristea M, Wang EW, Song M, Rodriguez-Rodriguez L, Yu H.
J Immunother Cancer. 2024 Apr 5;12(4):e007716. doi: 10.1136/jitc-2023-007716.
Histopathologic image-based deep learning classifier for predicting platinum-based treatment responses in high-grade serous ovarian cancer.
Ahn B, Moon D, Kim HS, Lee C, Cho NH, Choi HK, Kim D, Lee JY, Nam EJ, Won D, An HJ, Kwon SY, Shin SJ, Jung HR, Kwon D, Park H, Kim M, Cha YJ, Park H, Lee Y, Noh S, Lee YM, Choi SE, Kim JM, Sung SH, Park E.
Nat Commun. 2024 May 18;15(1):4253. doi: 10.1038/s41467-024-48667-6.
Trametinib response in heavily pretreated high-grade ovarian cancer: One step towards precision medicine.
Cappuccio S, Distefano MG, Ghizzoni V, Fagotti A, Scambia G.
Gynecol Oncol Rep. 2020 Feb 13;32:100547. doi: 10.1016/j.gore.2020.100547. eCollection 2020 May.
Pathological response of ovarian cancer to neoadjuvant chemotherapy.
Ivantsov AO.
Chin Clin Oncol. 2018 Dec;7(6):59. doi: 10.21037/cco.2018.09.07.
